04.11.24 – 06.11.24 • Stockholm, Sweden
BIO-EUROPE 2024
Are you going to attend the BIO-EUROPE 2024 in Stockholm? Meet Myllia's BD & Partnering team on site to explore CRISPR screens for early-stage R&D and target discovery
Thomas Moser, CEO, and Henrik Schmidt, BD Manager, are looking forward to discussing BIO-EUROPE 2024 partnerships in Stockholm, and to engage in stimulating discussions with prospects in the biotech and pharma industries. We seek to extend our research partnerships globally, with a particular emphasis on high-throughput phenotypic screening using CRISPR knockout, CRISPR interference and CRISPR activation in primary cells (e.g., epithelial cells, myeloid cells, and T cells). Our single-cell CRISPR screening (CROP-Seq, or Perturb-Seq) platform accelerates drug target ID and validation enabling reliable discoveries with functional genetic validation.
Event website:
BIO-EUROPE 2024
Attendee(s):
Henrik Schmidt (LinkedIn)
Thomas Moser (LinkedIn)